ATP8B3

Summary

ATP8B3 (ATPase phospholipid transporting 8B3, HGNC:13535) is a protein-coding gene on chromosome 19p13.3, encoding Phospholipid-transporting ATPase IK (O60423). P4-ATPase flippase which catalyzes the hydrolysis of ATP coupled to the transport of aminophospholipids from the outer to the inner leaflet of various membranes and ensures the maintenance of asymmetric distribution of phospholipids.

The protein encoded by this gene belongs to the family of P-type cation transport ATPases, and to the subfamily of aminophospholipid-transporting ATPases. The aminophospholipid translocases transport phosphatidylserine and phosphatidylethanolamine from one side of a bilayer to the other. This gene encodes member 3 of phospholipid-transporting ATPase 8B; other members of this protein family are located on chromosomes 1, 15 and 18. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.

Source: NCBI Gene 148229 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 314 total — 1 likely-pathogenic
• MANE Select transcript: NM_138813

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:13535
Approved symbol	ATP8B3
Name	ATPase phospholipid transporting 8B3
Location	19p13.3
Locus type	gene with protein product
Status	Approved
Aliases	ATPIK
Ensembl gene	ENSG00000130270
Ensembl biotype	protein_coding
OMIM	605866
Entrez	148229

Gene structure

Transcript identifiers

Ensembl transcripts: 8 — 4 protein_coding, 2 nonsense_mediated_decay, 1 retained_intron, 1 protein_coding_CDS_not_defined

ENST00000310127, ENST00000525591, ENST00000526092, ENST00000526847, ENST00000531925, ENST00000533107, ENST00000533993, ENST00000587160

RefSeq mRNA: 2 — MANE Select: NM_138813 NM_001178002, NM_138813

CCDS: CCDS45901, CCDS54196

Canonical transcript exons

ENST00000310127 — 29 exons

Exon	Start	End
ENSE00000655343	1792001	1792135
ENSE00001246630	1811489	1811884
ENSE00002165246	1782075	1783270
ENSE00002197461	1812186	1812276
ENSE00002836609	1806097	1806169
ENSE00003476114	1805888	1805958
ENSE00003480627	1810622	1810683
ENSE00003503834	1785469	1785708
ENSE00003509138	1796711	1796879
ENSE00003512589	1789361	1789727
ENSE00003515487	1789890	1789989
ENSE00003520444	1790757	1790832
ENSE00003533835	1805374	1805456
ENSE00003542141	1784819	1784946
ENSE00003543285	1801956	1802044
ENSE00003544148	1785159	1785297
ENSE00003560049	1787103	1787186
ENSE00003574407	1791750	1791861
ENSE00003588453	1802487	1802645
ENSE00003590682	1796974	1797005
ENSE00003613454	1808222	1808335
ENSE00003615677	1806628	1806689
ENSE00003618597	1796077	1796265
ENSE00003622804	1800259	1800449
ENSE00003625036	1788897	1789120
ENSE00003636843	1795875	1795987
ENSE00003655788	1799947	1800155
ENSE00003658002	1809643	1809734
ENSE00003785758	1807168	1807266

Expression profiles

Bgee: expression breadth ubiquitous, 169 present calls, max score 90.78.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 3.8830 / max 137.5809, expressed in 1161 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
178067	3.7426	1148
178065	0.0707	35
178066	0.0698	23

Top tissues by expression

278 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
left testis	UBERON:0004533	90.78	gold quality
right testis	UBERON:0004534	90.67	gold quality
testis	UBERON:0000473	88.40	gold quality
buccal mucosa cell	CL:0002336	87.52	gold quality
adult organism	UBERON:0007023	85.12	gold quality
stromal cell of endometrium	CL:0002255	80.63	gold quality
right adrenal gland	UBERON:0001233	77.14	gold quality
right adrenal gland cortex	UBERON:0035827	76.76	gold quality
granulocyte	CL:0000094	76.43	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	75.84	gold quality
left adrenal gland	UBERON:0001234	75.59	gold quality
left adrenal gland cortex	UBERON:0035825	75.10	gold quality
spleen	UBERON:0002106	74.91	gold quality
adrenal cortex	UBERON:0001235	73.89	gold quality
sperm	CL:0000019	73.06	silver quality
adrenal gland	UBERON:0002369	73.02	gold quality
male germ cell	CL:0000015	71.23	silver quality
leukocyte	CL:0000738	69.85	gold quality
monocyte	CL:0000576	69.82	gold quality
mononuclear cell	CL:0000842	69.63	gold quality
bone marrow cell	CL:0002092	68.85	gold quality
blood	UBERON:0000178	68.57	gold quality
right ovary	UBERON:0002118	68.43	gold quality
descending thoracic aorta	UBERON:0002345	68.25	gold quality
vagina	UBERON:0000996	67.98	gold quality
amniotic fluid	UBERON:0000173	67.86	silver quality
adrenal tissue	UBERON:0018303	67.76	gold quality
oocyte	CL:0000023	66.02	gold quality
vermiform appendix	UBERON:0001154	65.04	gold quality
ectocervix	UBERON:0012249	65.02	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	3.16

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

33 targeting ATP8B3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6759-5P	99.99	66.54	785
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-4778-3P	99.93	70.40	1818
HSA-MIR-6875-3P	99.82	70.26	2983
HSA-MIR-6842-5P	99.80	67.54	1587
HSA-MIR-7110-5P	99.80	67.84	1712
HSA-MIR-1976	99.74	65.48	1127
HSA-MIR-6887-3P	99.66	67.83	1778
HSA-MIR-103A-1-5P	99.39	67.78	1545
HSA-MIR-103A-2-5P	99.39	67.72	1577
HSA-MIR-5580-5P	99.38	66.96	1139
HSA-MIR-3064-5P	99.26	66.13	1497
HSA-MIR-3085-3P	99.26	66.16	1490
HSA-MIR-6504-5P	99.26	65.95	1487
HSA-MIR-149-5P	99.25	67.16	1315
HSA-MIR-3978	99.24	68.39	2201
HSA-MIR-4279	99.19	66.70	2437
HSA-MIR-511-5P	98.97	70.94	2268
HSA-MIR-29B-1-5P	98.86	68.35	1364
HSA-MIR-2355-5P	98.83	65.51	1589
HSA-MIR-138-5P	98.43	70.49	1292
HSA-MIR-4782-5P	98.35	69.33	1474
HSA-MIR-5706	98.35	69.33	1463
HSA-MIR-6826-3P	98.19	66.32	1153
HSA-MIR-6842-3P	98.07	66.33	1325
HSA-MIR-1245B-3P	98.01	68.91	1387
HSA-MIR-637	97.91	64.05	1517
HSA-MIR-3664-3P	97.85	67.62	1452
HSA-MIR-1289	97.46	65.37	655
HSA-MIR-10400-3P	97.29	64.66	597

Literature-anchored findings (GeneRIF, showing 1)

• Association of ATP8B3 gene polymorphisms with aspirin-exacerbated respiratory disease in asthmatics. (PMID:35997042)

Cross-species orthologs

8 orthologs

Organism	Symbol	Gene ID
danio_rerio	atp8b3	ENSDARG00000042285
mus_musculus	Atp8b3	ENSMUSG00000003341
rattus_norvegicus	Atp8b3	ENSRNOG00000024975
drosophila_melanogaster	CG9981	FBGN0030746
drosophila_melanogaster	CG4301	FBGN0030747
drosophila_melanogaster	CG31729	FBGN0051729
caenorhabditis_elegans	tat-5	WBGENE00009498
caenorhabditis_elegans		WBGENE00017174

Paralogs (13): ATP9A (ENSG00000054793), ATP11B (ENSG00000058063), ATP11A (ENSG00000068650), ATP8B1 (ENSG00000081923), ATP11C (ENSG00000101974), ATP8B4 (ENSG00000104043), ATP10B (ENSG00000118322), ATP8A1 (ENSG00000124406), ATP8A2 (ENSG00000132932), ATP8B2 (ENSG00000143515), ATP10D (ENSG00000145246), ATP9B (ENSG00000166377), ATP10A (ENSG00000206190)

Protein

Protein identifiers

Phospholipid-transporting ATPase IK — O60423 (reviewed: O60423)

Alternative names: ATPase class I type 8B member 3

All UniProt accessions (5): O60423, F5GZM8, F5H3R9, H0YFS1, K7EJ52

UniProt curated annotations — full annotation on UniProt →

Function. P4-ATPase flippase which catalyzes the hydrolysis of ATP coupled to the transport of aminophospholipids from the outer to the inner leaflet of various membranes and ensures the maintenance of asymmetric distribution of phospholipids. Phospholipid translocation also seems to be implicated in vesicle formation and in uptake of lipid signaling molecules. May be responsible for the maintenance of asymmetric distribution of phosphatidylserine (PS) in spermatozoa membranes. Involved in acrosome reactions and binding of spermatozoa to zona pellucida.

Subcellular location. Cytoplasmic vesicle. Secretory vesicle. Acrosome membrane. Endoplasmic reticulum membrane.

Tissue specificity. Isoform 3 was only detected in testis.

Miscellaneous. Association with flippase complex beta subunits TMEM30A and TMEM30A has not been detected, neither did their coexpression change the localization in ER.

Similarity. Belongs to the cation transport ATPase (P-type) (TC 3.A.3) family. Type IV subfamily.

Isoforms (3)

UniProt ID	Names	Canonical?
O60423-2	1	yes
O60423-1	2
O60423-3	3

RefSeq proteins (2): NP_001171473, NP_620168* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001757	P_typ_ATPase	Family
IPR006539	P-type_ATPase_IV	Family
IPR008250	ATPase_P-typ_transduc_dom_A_sf	Homologous_superfamily
IPR018303	ATPase_P-typ_P_site	PTM
IPR023214	HAD_sf	Homologous_superfamily
IPR023298	ATPase_P-typ_TM_dom_sf	Homologous_superfamily
IPR023299	ATPase_P-typ_cyto_dom_N	Homologous_superfamily
IPR032630	P_typ_ATPase_c	Domain
IPR032631	P-type_ATPase_N	Domain
IPR036412	HAD-like_sf	Homologous_superfamily
IPR044492	P_typ_ATPase_HD_dom	Domain

Pfam: PF13246, PF16209, PF16212

Catalyzed reactions (Rhea), 1 shown:

• a 1,2-diacyl-sn-glycero-3-phospho-L-serine(out) + ATP + H2O = a 1,2-diacyl-sn-glycero-3-phospho-L-serine(in) + ADP + phosphate + H(+) (RHEA:38567)

UniProt features (50 total): binding site 18, topological domain 11, transmembrane region 10, splice variant 3, region of interest 2, compositionally biased region 2, sequence variant 2, chain 1, active site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O60423-F1	75.37	0.24

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 495 (4-aspartylphosphate intermediate)

Ligand- & substrate-binding residues (18): 495; 495; 496; 497; 497; 596; 637; 660; 693; 763; 764; 765 …

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-936837	Ion transport by P-type ATPases
R-HSA-382551	Transport of small molecules
R-HSA-983712	Ion channel transport

MSigDB gene sets: 118 (showing top): GOBP_SINGLE_FERTILIZATION, GOCC_SECRETORY_GRANULE, MODULE_308, GOBP_REGULATION_OF_MEMBRANE_LIPID_DISTRIBUTION, GOBP_ORGANOPHOSPHATE_ESTER_TRANSPORT, GOCC_TRANS_GOLGI_NETWORK, NF1_Q6_01, GOBP_SPERM_EGG_RECOGNITION, GOBP_ENDOMEMBRANE_SYSTEM_ORGANIZATION, GOBP_PHOSPHOLIPID_TRANSPORT, GOBP_MEMBRANE_ORGANIZATION, GOBP_FERTILIZATION, GOBP_CELL_CELL_RECOGNITION, GOBP_LIPID_LOCALIZATION, GOBP_BINDING_OF_SPERM_TO_ZONA_PELLUCIDA

GO Biological Process (6): Golgi organization (GO:0007030), binding of sperm to zona pellucida (GO:0007339), phospholipid translocation (GO:0045332), establishment of localization in cell (GO:0051649), lipid transport (GO:0006869), phospholipid transport (GO:0015914)

GO Molecular Function (8): magnesium ion binding (GO:0000287), ATP binding (GO:0005524), ATP hydrolysis activity (GO:0016887), phosphatidylserine floppase activity (GO:0090556), ATPase-coupled intramembrane lipid carrier activity (GO:0140326), nucleotide binding (GO:0000166), transporter activity (GO:0005215), metal ion binding (GO:0046872)

GO Cellular Component (10): acrosomal membrane (GO:0002080), endoplasmic reticulum membrane (GO:0005789), trans-Golgi network (GO:0005802), plasma membrane (GO:0005886), membrane (GO:0016020), phospholipid-translocating ATPase complex (GO:1990531), acrosomal vesicle (GO:0001669), endoplasmic reticulum (GO:0005783), endomembrane system (GO:0012505), cytoplasmic vesicle (GO:0031410)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Ion channel transport	1
Transport of small molecules	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
ATP-dependent activity	2
cellular anatomical structure	2
cytoplasm	2
organelle organization	1
endomembrane system organization	1
sperm-egg recognition	1
phospholipid transport	1
lipid translocation	1
establishment of localization	1
cellular localization	1
transport	1
lipid localization	1
lipid transport	1
organophosphate ester transport	1
metal ion binding	1
adenyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
ribonucleoside triphosphate phosphatase activity	1
floppase activity	1
intramembrane lipid carrier activity	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
molecular_function	1
cation binding	1
acrosomal vesicle	1
secretory granule membrane	1
organelle membrane	1
nuclear outer membrane-endoplasmic reticulum membrane network	1
endoplasmic reticulum subcompartment	1
Golgi apparatus subcompartment	1
membrane	1
cell periphery	1
transporter complex	1
secretory granule	1
endomembrane system	1
intracellular membrane-bounded organelle	1
vacuole	1
plasma membrane	1
intracellular vesicle	1

Protein interactions and networks

STRING

1002 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ATP8B3	CDC50A	Q9NV96	578
ATP8B3	CDC50B	Q3MIR4	550
ATP8B3	MS4A14	Q96JA4	426
ATP8B3	SLC35F1	Q5T1Q4	395
ATP8B3	FDXACB1	Q9BRP7	393
ATP8B3	ATP6AP1L	Q52LC2	393
ATP8B3	SLC4A9	Q96Q91	386
ATP8B3	C19orf25	Q9UFG5	371
ATP8B3	SPAG17	Q6Q759	348
ATP8B3	DYNLT2	Q8IZS6	348
ATP8B3	ZNF710	Q8N1W2	344
ATP8B3	DCDC2B	A2VCK2	343
ATP8B3	MMP27	Q9H306	324
ATP8B3	CLSTN2	Q9H4D0	322
ATP8B3	SLC13A1	Q9BZW2	317

IntAct

5 interactions, top by confidence:

A	B	Type	Score
ATP8B3	SPTAN1	psi-mi:“MI:0915”(physical association)	0.400
MAPT	SHTN1	psi-mi:“MI:0914”(association)	0.350

BioGRID (6): ATP8B3 (Affinity Capture-RNA), SPTAN1 (Proximity Label-MS), ATP8B3 (Affinity Capture-MS), ATP8B3 (Negative Genetic), ATP8B3 (Affinity Capture-MS), ATP8B3 (Affinity Capture-RNA)

ESM2 similar proteins: A3FIN4, D3K0R6, D4AA47, O14072, O23087, O43520, O60423, O75185, O94296, P22189, P23634, P39524, P54678, P57709, P90747, P98194, P98196, P98197, P98198, P98199, P98204, P98205, Q09891, Q10309, Q148W0, Q21286, Q27533, Q3TYU2, Q42883, Q4VNC0, Q4VNC1, Q5BL50, Q5XF90, Q5ZKB7, Q64542, Q6DFW5, Q6Q477, Q6UQ17, Q7XB51, Q8NB49

Diamond homologs: A1A4J6, A3FIN4, B1AWN4, C7EXK4, D4AA47, D4ABB8, F1Q4S1, G0S196, G2X7W6, G5EBH1, O36028, O43520, O43861, O54827, O60312, O60423, O94296, O94823, P32660, P39524, P40527, P57792, P70704, P98195, P98196, P98197, P98198, P98199, P98200, P98204, P98205, Q09891, Q10309, Q12675, Q148W0, Q29449, Q37145, Q5BL50, Q6DFW5, Q6UQ17

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

314 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	1
Uncertain significance	259
Likely benign	32
Benign	7

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
425154	NM_138813.4(ATP8B3):c.1009C>T (p.Arg337Ter)	Likely pathogenic

SpliceAI

6073 predictions. Top by Δscore:

Variant	Effect	Δscore
19:1784814:CTCA:C	donor_loss	1.0000
19:1784817:ACCTT:A	donor_loss	1.0000
19:1784829:AGCT:A	donor_gain	1.0000
19:1784830:G:C	donor_gain	1.0000
19:1784907:A:T	acceptor_gain	1.0000
19:1785186:CT:C	donor_gain	1.0000
19:1787193:C:CT	acceptor_gain	1.0000
19:1787193:C:T	acceptor_gain	1.0000
19:1787194:G:T	acceptor_gain	1.0000
19:1788892:CGCA:C	donor_loss	1.0000
19:1788893:GCA:G	donor_loss	1.0000
19:1788894:CACC:C	donor_loss	1.0000
19:1788895:A:C	donor_loss	1.0000
19:1788896:C:CA	donor_loss	1.0000
19:1789117:GCGG:G	acceptor_gain	1.0000
19:1789118:CGG:C	acceptor_gain	1.0000
19:1789118:CGGC:C	acceptor_gain	1.0000
19:1789120:GCT:G	acceptor_loss	1.0000
19:1789121:C:CC	acceptor_gain	1.0000
19:1789121:CTG:C	acceptor_loss	1.0000
19:1789359:A:AC	donor_gain	1.0000
19:1789360:C:CC	donor_gain	1.0000
19:1789360:CT:C	donor_gain	1.0000
19:1789424:T:TA	donor_gain	1.0000
19:1789424:TCTTG:T	donor_gain	1.0000
19:1790751:TCTTA:T	donor_loss	1.0000
19:1790752:CTTA:C	donor_loss	1.0000
19:1790753:TTA:T	donor_loss	1.0000
19:1790755:ACC:A	donor_loss	1.0000
19:1790756:C:CA	donor_loss	1.0000

AlphaMissense

8557 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
19:1789378:T:G	D943A	0.998
19:1800015:T:G	D495A	0.997
19:1789378:T:A	D943V	0.996
19:1789394:C:A	G938W	0.996
19:1789402:A:G	L935P	0.996
19:1791774:A:G	W760R	0.996
19:1791774:A:T	W760R	0.996
19:1800015:T:A	D495V	0.996
19:1805935:G:C	S258R	0.996
19:1805935:G:T	S258R	0.996
19:1805937:T:G	S258R	0.996
19:1789377:G:C	D943E	0.995
19:1789377:G:T	D943E	0.995
19:1800016:C:G	D495H	0.995
19:1789379:C:G	D943H	0.994
19:1789393:C:T	G938E	0.994
19:1789399:G:T	A936D	0.994
19:1789400:C:G	A936P	0.994
19:1791767:A:G	L762P	0.994
19:1789009:C:T	G986D	0.993
19:1802598:C:A	G318W	0.993
19:1789378:T:C	D943G	0.992
19:1789475:A:G	C911R	0.992
19:1789480:A:T	V909D	0.992
19:1789490:A:G	C906R	0.992
19:1791797:A:G	L752P	0.992
19:1796091:C:G	R643P	0.992
19:1796108:G:C	F637L	0.992
19:1796108:G:T	F637L	0.992
19:1796110:A:G	F637L	0.992

dbSNP variants (sampled 300 via entrez): RS1000051791 (19:1810988 C>T), RS1000093288 (19:1798573 T>C), RS1000176746 (19:1788637 G>C), RS1000278363 (19:1792758 A>C), RS1000387416 (19:1803810 C>G,T), RS1000438143 (19:1794070 C>T), RS1000566212 (19:1811815 C>A,T), RS1000621471 (19:1787756 A>C,T), RS1000678039 (19:1807007 C>G), RS1000761433 (19:1784062 A>G,T), RS1000778562 (19:1787986 G>A,C), RS1000793692 (19:1806822 C>A,T), RS1000832168 (19:1797267 G>A), RS1001041997 (19:1793201 C>A,T), RS1001093557 (19:1797468 T>A)

Disease associations

OMIM: gene MIM:605866 | disease phenotypes: MIM:189800

GenCC curated gene-disease

Mondo (1): preeclampsia (MONDO:0005081)

Orphanet (1): Preeclampsia (Orphanet:275555)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST001762_341	Obesity-related traits	7.000000e-06
GCST008972_185	Urate levels	4.000000e-09

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004531	urate measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011225	Pre-Eclampsia	C12.050.703.395.249

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB variants

3 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs10421558	ATP8B3		0.00	0
rs10403288	ATP8B3		0.00	0
rs45574836	ATP8B3		0.00	0

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: transporter — P4 P-type ATPases: Phospholipid-transporting ATPases

CTD chemical–gene interactions

48 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, increases methylation, affects cotreatment, increases expression	9
sodium arsenite	decreases expression, affects cotreatment, increases abundance	2
entinostat	increases expression, affects cotreatment	2
Panobinostat	affects cotreatment, increases expression	2
Benzo(a)pyrene	increases methylation, increases mutagenesis	2
Estradiol	affects cotreatment, increases expression, affects expression, increases reaction	2
triphenyl phosphate	affects expression	1
propionaldehyde	increases expression	1
bisphenol A	affects cotreatment, increases methylation, decreases methylation	1
lead acetate	decreases expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
butyraldehyde	increases expression	1
perfluorooctanoic acid	increases expression	1
manganese chloride	decreases expression, increases abundance, affects cotreatment	1
benzo(e)pyrene	increases methylation	1
cupric chloride	decreases expression	1
pentanal	increases expression	1
perfluorooctane sulfonic acid	decreases expression	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
ICG 001	increases expression	1
abrine	increases expression	1
ormosil	affects binding, decreases expression	1
dorsomorphin	affects cotreatment, increases expression	1
bisphenol S	increases methylation	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	increases expression	1
Sunitinib	decreases expression	1
Fulvestrant	affects cotreatment, increases methylation	1
Acetaminophen	decreases expression	1
Air Pollutants	decreases expression, increases abundance	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00117546	PHASE4	UNKNOWN	Cardiovascular and Autonomic Reactivity in Women With a History of Pre-eclampsia
NCT00567957	PHASE4	UNKNOWN	Remifentanil for General Anesthesia in Preeclamptics
NCT01030627	PHASE4	COMPLETED	Treatment Approaches to Preeclampsia
NCT01352234	PHASE4	COMPLETED	Comparison of Doses of Acetylsalicylic Acid in Women With Previous History of Preeclampsia
NCT01361425	PHASE4	UNKNOWN	Anti-Hypertensive Treatment In Stable Pregnant Women With Severe Pre-Eclampsia (Metildopape)
NCT01729468	PHASE4	COMPLETED	Prevention of Pre-eclampsia and SGA by Low-Dose Aspirin in Nulliparous Women With Abnormal First-trimester Uterine Artery Dopplers
NCT01761916	PHASE4	COMPLETED	Clonidine Versus Captopril for Treatment of Postpartum Very High Blood Pressure
NCT01912677	PHASE4	COMPLETED	Oral Antihypertensive Regimens for Management of Hypertension in Pregnancy
NCT02025426	PHASE4	TERMINATED	Phenylephrine Versus Ephedrine in Pre-eclampsia
NCT02091401	PHASE4	COMPLETED	A Trial Comparing Treatment With the Springfusor Infusion Pump to the IV Magnesium Sulfate Regimen
NCT02163655	PHASE4	COMPLETED	Diuretics for Postpartum High Blood Pressure in Preeclampsia
NCT02338687	PHASE4	COMPLETED	Low Dose Calcium to Prevent Preeclampsia
NCT02396030	PHASE4	TERMINATED	Different Schemes of Magnesium Sulfate for Preeclampsia
NCT02531490	PHASE4	UNKNOWN	Early Vascular Adjustments During Hypertensive Pregnancy
NCT02699827	PHASE4	COMPLETED	Adding MgSO4 to Epidural Levobupivacaine in CS for Patients With Preeclampsia
NCT02835339	PHASE4	COMPLETED	Magnesium Sulfate in Obese Preeclamptics
NCT02891174	PHASE4	COMPLETED	The Effect of Ibuprofen on Post-partum Blood Pressure in Women With Hypertensive Disorders of Pregnancy
NCT02911701	PHASE4	COMPLETED	Effect of Acetaminophen on Postpartum Blood Pressure Control in Preeclampsia With Severe Features
NCT03171480	PHASE4	COMPLETED	Use of Nitrous Oxide Donor for Labor Induction in Women With PreEclampsia
NCT03233880	PHASE4	UNKNOWN	Impact of Antichlamydial Treatment on the Rate of Preeclampsia
NCT03237000	PHASE4	UNKNOWN	Effect of Administering Intravenous Magnesium Sulfate on Fetal Cardiotocography and Neonatal Outcome in Preeclamptic Patients
NCT03506724	PHASE4	COMPLETED	Response to Anti-hypertensives in Pregnant and Postpartum Patients
NCT03674606	PHASE4	COMPLETED	Trial of Early Screening Test for Pre-eclampsia and Growth Restriction
NCT03735433	PHASE4	TERMINATED	The Effect of Two Aspirin Dosing Strategies for Obese Women at High Risk for Preeclampsia
NCT03824119	PHASE4	UNKNOWN	Postpartum NSAIDS and Maternal Hypertension
NCT04051567	PHASE4	UNKNOWN	Low-dose Aspirin for Prevention of Adverse Pregnancy Outcomes in Twin Pregnancies
NCT04077853	PHASE4	COMPLETED	Progesterone in Expectantly Managed Early-onset Preeclampsia
NCT04158830	PHASE4	WITHDRAWN	Aspirin (ASA) Therapy and Preeclampsia Prevention
NCT04424693	PHASE4	UNKNOWN	Comparing the Incidence of Preeclampsia Between Pregnant Women Receiving Tdap Vaccinations at Week 28 or at Week 36
NCT04631627	PHASE4	UNKNOWN	Early Prediction and Randomised Prevention of Preeclampsia With Low Dose Aspirin in Chinese Cohort
NCT04656665	PHASE4	UNKNOWN	The Effectiveness of Aspirin on Preventing Pre-eclampsia
NCT04797949	PHASE4	WITHDRAWN	Adherence to Universal Aspirin Compared to Screening Indicated Aspirin for Prevention of Preeclampsia
NCT04908982	PHASE4	UNKNOWN	Aspirin for the Prevention of Preeclampsia in Women With Stage 1 Hypertension
NCT05221164	PHASE4	UNKNOWN	162 mg of Aspirin for Prevention of Preeclampsia
NCT05294952	PHASE4	UNKNOWN	co Ihibtory Receptor in Preeclampsia
NCT05514847	PHASE4	ACTIVE_NOT_RECRUITING	Low Dose Aspirin for Preterm Preeclampsia Preventionmg/day Dose in High-risk Patients
NCT05586373	PHASE4	COMPLETED	Ibuprofen vs Dipyrone After C-section in Preeclampsia
NCT06069102	PHASE4	COMPLETED	Optimal Blood Pressure Treatment Thresholds Postpartum
NCT06107335	PHASE4	NOT_YET_RECRUITING	Effect of Albumin Versus Routine Care on Hemodynamic Response and Stability in Patients With Preeclampsia Guided by a Non-invasive Hemodynamic Monitoring System During Cesarean Delivery With Spinal Anesthesia
NCT06281665	PHASE4	RECRUITING	Treatment With Aspirin After Preeclampsia: TAP Trial